List view / Grid view
30 March 2016 | By Victoria White
The trial of IMCgp100 will include three Phase I escalation cohorts to determine the optimal dose for the Phase II study, which is expected to start in 2016...
30 March 2016 | By Victoria White
Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy...
29 March 2016 | By Victoria White
The US District Court for Southern Florida has upheld Shire's patent for Lialda (mesalamine) delayed release tablets for adults with ulcerative colitis...
29 March 2016 | By Victoria White
A total of 340 late-breaker abstracts have been submitted to ECCMID: 25 are related to refugee health, 44 to colistin resistance, and 271 on other topics...
29 March 2016 | By Victoria White
The study will assess Visco-ease’s ability to restore the function of saliva in patients undergoing radiotherapy for the treatment of Head and Neck Cancer...
29 March 2016 | By Victoria White
The FDA have issued a CRL to include new data in the clinical trials section of the US label of Brintellix for treating aspects of cognitive dysfunction in MDD...
29 March 2016 | By Victoria White
The ARCHES trial will evaluate the efficacy and safety of enzalutamide with androgen deprivation therapy (ADT) versus placebo with ADT in mHSPC patients...
24 March 2016 | By Victoria White
Regeneron and Bayer are to develop a combination therapy of the Ang2 antibody nesvacumab and the VEGF trap aflibercept for the treatment of eye diseases...
24 March 2016 | By Victoria White
Aprecia’s Spritam (levetiracetam) tablets, for oral suspension, are now available in the US as an adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures.
24 March 2016 | By Victoria White
Xeljanz is the only oral Janus kinase (JAK) inhibitor approved in more than 45 countries around the world for the treatment of moderate to severe RA...
23 March 2016 | By Victoria White
CSL Behring’s Idelvion and Sobi/Biogen’s Alprolix will compete intensely for a share of the haemophilia B market following their expected European approvals...
23 March 2016 | By Victoria White
Polyphor's POL6014 reduces the activity of elastase, an enzyme that destroys lung tissue when it is produced in excess...
23 March 2016 | By CPhI
CPhI Japan, organised by UBM EMEA, will take place at the Big Sight Exhibition Centre, Tokyo, Japan, 20th-22nd April...
23 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will be presenting as part of the biotech track at the 10th annual BioTrinity 2016 conference in London, April 25-27...
The National Institute for Health and Care Excellence (NICE) has issued draft guidance which does not recommend Vertex Pharmaceuticals’ Orkambi (lumacaftor-ivacaftor) for treating cystic fibrosis.
